Artem

About Artem Andrianov, Ph.D., MBA

Professional in the integration of data-driven Risk-based Monitoring (RbM) process in international clinical trials of pharmacology. Speaker at regional and global conferences such as: DIA, PharmaForum, PharmaDay, DGGF, etc. 10+ years of experience in data quality projects and biostatistics for the pharmaceutical industry. Life passion: improving clinical research with RbM, driving the RbM research to new frontiers for CROs, pharma and biotech companies.
May 2019

Centralized Monitoring: a Greater Advantage to a Broader Range of Trials

By |2019-05-07T09:37:52+00:00May 2, 2019|Blog, Infographic|0 Comments

Regulatory bodies are unanimous, today's clinical research needs Centralized Monitoring. We summarized Centralized Monitoring the infographic way, download your free copy here...

Apr 2019

RBM Software Features: What’s a Risk Flower chart?

By |2019-04-09T12:43:18+00:00April 9, 2019|Blog, Neat Features|1 Comment

Neat Features: wanting to dig a little deeper into the neat software features that make your risk-management life easy? Well, you’ve come to the right place. Learn more about Risk Flowers charts - a bunch of information.

Jan 2019

Quality Tolerance Limits versus Key Risk Indicators, The Difference

By |2019-01-25T08:26:29+00:00January 18, 2019|Blog, Infographic|0 Comments

To clear up confusion surrounding the interpretation and use of QTLs and KRIs, we have created an easy to understand infographic for all clinical research experts involved in quality control.

Nov 2018

Patient Profiles – Better Understand Your Patients

By |2018-11-20T10:25:21+00:00November 1, 2018|Blog, Neat Features, RBM Product Updates|0 Comments

Pharma today embraces the concept of patient-centered research. Innovators view Patients as informed collaborators whose participation is core to the overall success of clinical research. The risk-based Patient Profiles tool is a key contributor to the modern concept of patient-centered thinking, as It enables early detection and real time control of patient safety issues.

Jul 2018

Press Release: Cyntegrity enters the Medical Devices Market

By |2019-04-02T11:07:31+00:00July 10, 2018|News|0 Comments

Cyntegrity today announced the worldwide release of their Medical Device RACT, “MD-RACT”, the world’s first Risk Assessment and Categorization Tool for clinical investigations, that combines the best practices in Life Sciences with subject matter expertise in Medical Devices.

May 2018

Key Risk Indicators Reveal Blind Spots in Clinical Trials

By |2018-05-16T09:02:30+00:00May 15, 2018|Blog|0 Comments

By design, the traditional spot-checking type of audits leave a blind spot on systemic quality threats. Key Risk Indicators however, form the core of a widely applicable concept that captures all relevant risks in scope and provides project managers and QM experts targeted and objective updates on actionable issues and trends.

Mar 2018

A Simple 5-step Plan to Improve Quality and Efficiency in Clinical Trials

By |2018-03-16T12:10:26+00:00March 2, 2018|News|0 Comments

Last February 28th, the FDA finalized the E6 (R2) version of the addendum to the International Council for Harmonisation's (ICH) good clinical practice (GCP) guideline. What to do now? Don’t panic, we’ve put together a simple 5-step plan to help you initiate the most urgent process adaptations.

Register Today!

Get Free Test Access